SMS PHARMACEUTICALS
|
SMS PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 5.89 | -0.83 | 7.35 | 7.39 | 3.73 |
| CEPS(Rs) | 9.54 | 4.25 | 11.82 | 9.83 | 6.47 |
| DPS(Rs) | 0.40 | 0.30 | 0.30 | 0.30 | 0.25 |
| Book NAV/Share(Rs) | 59.98 | 54.40 | 55.56 | 48.50 | 41.14 |
| Tax Rate(%) | 25.57 | 27.39 | 0.90 | 33.09 | 35.60 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.55 | 9.87 | 20.69 | 19.94 | 17.75 |
| EBIT Margin(%) | 11.94 | 4.94 | 15.83 | 16.84 | 13.99 |
| Pre Tax Margin(%) | 8.80 | 0.97 | 12.37 | 15.00 | 11.26 |
| PAT Margin (%) | 6.55 | 0.70 | 12.25 | 10.04 | 7.25 |
| Cash Profit Margin (%) | 10.75 | 6.52 | 18.06 | 13.70 | 12.14 |
| Performance Ratios | |||||
| ROA(%) | 5.10 | 0.44 | 7.97 | 8.44 | 5.50 |
| ROE(%) | 10.16 | 0.83 | 15.41 | 16.07 | 9.76 |
| ROCE(%) | 11.73 | 3.79 | 12.60 | 17.62 | 13.06 |
| Asset Turnover(x) | 0.78 | 0.63 | 0.65 | 0.84 | 0.76 |
| Sales/Fixed Asset(x) | 1.24 | 0.97 | 0.98 | 1.32 | 1.29 |
| Working Capital/Sales(x) | 3.71 | 3.55 | 3.07 | 5.33 | 6.13 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.80 | 1.04 | 1.02 | 0.76 | 0.78 |
| Receivable days | 93.46 | 65.01 | 50.80 | 46.40 | 30.27 |
| Inventory Days | 111.10 | 156.71 | 128.12 | 80.21 | 107.49 |
| Payable days | 111.30 | 97.98 | 91.63 | 59.01 | 68.29 |
| Valuation Parameters | |||||
| PER(x) | 30.25 | - | 12.76 | 16.84 | 7.15 |
| PCE(x) | 18.67 | 13.59 | 7.94 | 12.65 | 4.12 |
| Price/Book(x) | 2.97 | 1.06 | 1.69 | 2.57 | 0.65 |
| Yield(%) | 0.22 | 0.52 | 0.32 | 0.24 | 0.94 |
| EV/Net Sales(x) | 2.47 | 1.41 | 1.94 | 2.24 | 0.89 |
| EV/Core EBITDA(x) | 14.45 | 12.35 | 8.41 | 10.14 | 4.33 |
| EV/EBIT(x) | 19.52 | 26.88 | 11.49 | 12.35 | 5.84 |
| EV/CE(x) | 2.14 | 1.03 | 1.15 | 1.53 | 0.60 |
| M Cap / Sales | 2.13 | 0.94 | 1.53 | 1.87 | 0.55 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 35.86 | 0.42 | -7.69 | 36.71 | -11.39 |
| Core EBITDA Growth(%) | 103.90 | -50.38 | -3.83 | 46.34 | -8.99 |
| EBIT Growth(%) | 228.30 | -68.83 | -14.31 | 62.21 | -15.09 |
| PAT Growth(%) | 1,166.70 | -94.28 | 11.34 | 86.50 | -21.14 |
| EPS Growth(%) | 805.84 | -111.35 | -0.49 | 98.04 | -21.16 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.55 | 0.55 | 0.55 | 0.61 | 0.44 |
| Current Ratio(x) | 1.58 | 1.61 | 1.85 | 1.54 | 1.48 |
| Quick Ratio(x) | 0.91 | 0.73 | 0.67 | 0.89 | 0.64 |
| Interest Cover(x) | 3.80 | 1.24 | 4.57 | 9.14 | 5.12 |
| Total Debt/Mcap(x) | 0.19 | 0.52 | 0.33 | 0.24 | 0.68 |
Compare Financial Ratios of peers of SMS PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SMS PHARMACEUTICALS | ₹1,834.6 Cr | 8.4% | -4.8% | 64.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹419,764.0 Cr | 0.6% | -2.1% | 16.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,010.0 Cr | 4.3% | 6.5% | 63.9% | Stock Analytics | |
| CIPLA | ₹118,905.0 Cr | 3.6% | 0.2% | 2.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,523.0 Cr | 3% | -8.4% | 0% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹100,015.0 Cr | 3.2% | -1% | 27.4% | Stock Analytics | |
SMS PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SMS PHARMACEUTICALS | 8.4% |
-4.8% |
64.9% |
| SENSEX | 0.5% |
0.3% |
7.9% |
You may also like the below Video Courses
